## Systemic Therapy Update



March 2013 Volume 16, Supplement 1

## For Health Professionals Who Care For Cancer Patients

## **ERRATUM**

## **PROTOCOL CODING FOR HYDROXYUREA**

In the article titled "Protocol Coding for Hydroxyurea" in the March 2013 issue of the Systemic Therapy Update, please note the **corrections** in the table below:

Approved Hydroxyurea Indications at the BCCA	Correct Protocol Code
MYELOID NEOPLASMS	
Acute myeloid leukemia	LKNOS
Myelodysplastic syndromes, including:	LKNOS
Refractory anemia	
Aplastic anemia	
Preleukemic syndrome	
Myeloproliferative disease, including:	LKNOS
Chronic myeloid leukemia	
Polycythemia (i.e., polycythemia rubra vera)	
Essential thrombocythemia (i.e., thrombocythemia thrombosis)	
Myelofibrosis	
LYMPHOID NEOPLASMS	
Cryoglobulinemia	LYNOS
Lymphoproliferative disease	LYNOS
Waldenstrom's macroglobulinemia	LYNOS